15.5 Introduction to Modern Pharmacology vis-à-vis Materia Medica
Key Takeaways
- NCH names the subject "Practice of Medicine with Introduction to Modern Pharmacology" and gives modern pharmacology its own third-professional code (HomUG-Mod.Phar)
- Pharmacokinetics is what the body does to the drug (ADME); pharmacodynamics is what the drug does to the body (receptors, agonism, dose-response)
- Therapeutic index = LD50 ÷ ED50 — a larger index means a wider safety margin, and steady state is reached after roughly four to five half-lives
- Type A adverse reactions are augmented, dose-related and predictable; Type B are bizarre, non-dose-related and idiosyncratic
- Organon §74 warns that prolonged allopathic drugging produces artificial chronic disease — drug-induced symptoms must be separated from the natural disease before repertorising
15.5 Introduction to Modern Pharmacology vis-à-vis Materia Medica
Quick Answer: Pharmacokinetics = ADME (what the body does to the drug). Pharmacodynamics = receptor action and dose-response (what the drug does to the body). Therapeutic index = LD50 ÷ ED50. Steady state arrives after 4-5 half-lives. Type A adverse reactions are dose-related and predictable; Type B are idiosyncratic. Organon §74 is the bridge: chronic allopathic drugging creates artificial disease that contaminates the case image.
The NCH regulations do not treat this as optional. Modern pharmacology appears twice — folded into the Practice of Medicine subject title, and again as a third-professional subject taught explicitly vis-à-vis Homoeopathic Materia Medica. The clinical reason is blunt: almost every chronic patient who walks into a homoeopathic OPD is already on conventional medication, and you cannot take an honest case without knowing which symptoms the pharmacy produced.
Pharmacokinetics — ADME
| Phase | What happens | Exam handle |
|---|---|---|
| Absorption | Drug moves from the site of administration into plasma | Bioavailability = fraction reaching systemic circulation unchanged; IV bioavailability = 100% |
| Distribution | Drug moves from plasma into tissues | Volume of distribution; plasma protein binding (bound fraction is inactive and non-filterable) |
| Metabolism | Chemical alteration, chiefly hepatic | First-pass metabolism reduces oral bioavailability; Phase I (oxidation/reduction/hydrolysis, cytochrome P450) then Phase II (conjugation) |
| Excretion | Removal, chiefly renal | Renal impairment prolongs half-life of renally cleared drugs |
Half-life arithmetic worth memorising
Half-life (t½) is the time for plasma concentration to fall by half. On regular dosing, plasma level plateaus at steady state after approximately 4-5 half-lives — and, symmetrically, roughly 4-5 half-lives are needed for near-complete washout after stopping. A drug with a 12-hour half-life therefore takes about two to two-and-a-half days to reach steady state, which is why a patient's "new" symptom on day three of a conventional drug may be a pharmacological effect rather than disease progression.
Pharmacodynamics
| Term | Definition |
|---|---|
| Receptor | Macromolecule the drug binds to produce an effect |
| Agonist | Binds and activates the receptor |
| Antagonist | Binds with affinity but zero intrinsic activity; blocks the agonist |
| Partial agonist | Submaximal response even at full receptor occupancy |
| Affinity | Tendency to bind the receptor |
| Efficacy | Maximal effect the drug can produce |
| Potency | Dose required to produce a given effect |
| ED50 | Dose effective in 50% of the population |
| LD50 | Dose lethal in 50% of the test population |
| Therapeutic index | LD50 ÷ ED50 — larger means safer |
Classic distractor: potency and efficacy are swapped constantly. A very potent drug simply works at a smaller dose; it may still have low efficacy. A drug with a narrow therapeutic index (digoxin, lithium, warfarin, phenytoin, aminoglycosides) needs monitoring because the toxic dose sits close to the effective one.
Adverse Drug Reactions
| Category | Nature | Examples of the pattern |
|---|---|---|
| Type A (Augmented) | Dose-related, predictable from the drug's known pharmacology, common, low mortality | Bleeding on an anticoagulant; hypoglycaemia on insulin; bradycardia on a beta-blocker |
| Type B (Bizarre) | Not dose-related, unpredictable, uncommon, higher mortality | Anaphylaxis; idiosyncratic hepatotoxicity; severe cutaneous drug reactions |
Related vocabulary you should be able to separate cleanly: side effect (unwanted but pharmacologically expected at therapeutic dose), toxic effect (from excessive dose or accumulation), idiosyncrasy (genetically determined abnormal response), allergy (immunologically mediated), teratogenicity (fetal malformation), tolerance (diminishing response on repetition), dependence, and withdrawal/rebound.
Where Modern Pharmacology Meets Materia Medica
Several substances appear in both systems, which is exactly why the Commission asks you to study them side by side.
| Substance | Modern pharmacology view | Homoeopathic view |
|---|---|---|
| Digitalis purpurea | Cardiac glycoside; positive inotrope, narrow therapeutic index | Slow weak irregular pulse, fear the heart will stop on movement |
| Belladonna / atropine | Muscarinic antagonist; mydriasis, dry mouth, flushing, tachycardia | Sudden violent congestion, red hot face, throbbing, dilated pupils |
| Opium | Opioid agonist; analgesia, miosis, respiratory depression, constipation | Painless torpor, stupor, obstinate constipation without urging |
| Mercury | Heavy-metal toxicant; stomatitis, salivation, nephrotoxicity | Offensive salivation, creeping chill, night aggravation, ulceration |
The methodological contrast is the actual exam point. Conventional pharmacology characterises a material dose-response relationship in disease, quantified through Phase I-IV clinical trials. Homoeopathic drug proving (Homoeopathic Pathogenetic Trial) records the totality of symptoms produced by the substance in healthy provers, subjective symptoms included, and it is that pathogenetic picture — not the pharmacological mechanism — that authorises the prescription. Same substance; incompatible frameworks; do not answer a proving question with a receptor mechanism.
Organon §74 — Artificial Chronic Disease
Hahnemann attacks prolonged, aggressive allopathic drugging as a producer of artificial chronic diseases superimposed on the natural one. Two practical consequences for case-taking:
- Separate the layers. Symptoms that began after a drug was started, are dose-related, and fit that drug's known pharmacology are candidates for drug effect rather than characteristic disease symptoms. Repertorising a beta-blocker's bradycardia as a general is a false totality.
- Do not mistake withdrawal for aggravation. A rebound on abrupt cessation is not a homoeopathic aggravation and does not confirm the remedy.
Never stop these abruptly
Corticosteroids, antiepileptics, beta-blockers and other antihypertensives, insulin and oral hypoglycaemics, antithyroid drugs, anticoagulants, and psychotropics all carry real rebound or crisis risk on sudden withdrawal. Tapering is the treating physician's decision and belongs in a co-management conversation — not a unilateral instruction from the homoeopathic side. AIAPGET stems test this as a patient-safety judgement, and the safe answer is always coordinate and taper, never "stop everything so the remedy can act."
Compact Revision Card
- ADME = absorption, distribution, metabolism, excretion
- Bioavailability IV = 100%; oral reduced by first-pass metabolism
- Steady state ≈ 4-5 half-lives
- Therapeutic index = LD50 ÷ ED50; narrow-index drugs need monitoring
- Potency = dose needed; efficacy = ceiling effect — never interchange
- Type A dose-related and predictable; Type B idiosyncratic and bizarre
- §74 artificial chronic disease from allopathic maltreatment
- Proving is on the healthy; clinical trials are on the diseased
A drug has an LD50 of 900 mg/kg and an ED50 of 30 mg/kg. What is its therapeutic index, and what does the value indicate?
A patient begins a drug with a half-life of about 8 hours on a fixed regular dosing schedule. Approximately when should plasma concentration reach steady state?
Which pairing correctly matches an adverse drug reaction to its classification?
What is the essential methodological difference between a homoeopathic drug proving and a conventional Phase I clinical trial?
A patient on long-term oral corticosteroids for a chronic condition asks whether to stop the drug immediately so the homoeopathic remedy can act. What is the correct response?